Flavia Michelini

5PUBLICATIONS
37CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Apr 09, 2026
Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Vicky Makker, Jung-Yun Lee, Do-Youn Oh

|Feb 11, 2026
HER2 testing in multiple solid tumor types: concordance of immunohistochemistry scores between three HER2 scoring algorithms.

Sunil S Badve, Michelle Shiller, Wentao Yang

|Apr 20, 2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.

Daniel A King, Amber R Smith, Gino Pineda

|Apr 10, 2019
RNase A treatment and reconstitution with DNA damage response RNA in living cells as a tool to study the role of non-coding RNA in the formation of DNA damage response foci.

Flavia Michelini, Francesca Rossiello, Fabrizio d'Adda di Fagagna

Pageof 1

Frequent Collaborators

2 joint publications

Funda Meric-Bernstam

2 joint publications

Ana Oaknin

2 joint publications

Jung-Yun Lee

2 joint publications

Vicky Makker